Soluble tumor necrosis factor-α receptor type 1 during selenium supplementation in psoriasis patients

Nutrition

Volumn 19, Issue 10, 2003, Pages 847-850

  Serwin, Agnieszka B ^a   Mysliwiec, Hanna ^a   Hukalowicz, Katarzyna ^a   Porebski, Piotr ^a   Borawska, Maria ^a   Chodynicka, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Psoriasis; Selenium supplementation; sTNF R1

Indexed keywords

DITHRANOL; SALICYLIC ACID; SELENOMETHIONINE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; OINTMENT; PARAMETRIC TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SKIN DEFECT; STATISTICAL ANALYSIS; TOPICAL TREATMENT; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0141953226     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(03)00165-5     Document Type: Article

References (25)

1. Rayman M.P. The importance of selenium to human health. Lancet. 356:2002;233.
2. Roy M., Kiremidjian-Schumacher L., Wishe H.T., Cohen M.W., Stocky G. Effect of selenium on expression of high affinity interleukin 2 receptors. Proc Soc Biol Med. 200:1992;36.
3. Celerier P., Richard A., Litoux P., Dreno B. Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines. Arch Dermatol Res. 287:1995;680.
4. Michaelsson G., Berne B., Carlmark B., Strand A. Selenium in whole blood and plasma is decreased in patients with moderate and severe psoriasis. Acta Derm Venereol (Stockh). 69:1989;29.
5. Fairris G.M., Lloyd B., Hinks L., Perkins P.J., Clayton B.E. The effect of supplementation with selenium and vitamin E in psoriasis. Ann Clin Biochem. 26:1989;83.
6. Serwin A.B., Wasowicz W., Gromadzinska J., Chodynicka B. Selenium status in psoriasis and its relationship with the severity of the disease. Nutrition. 19:2003;301.
7. Pinton J., Friden H., Kettaneh-Wold N., et al. Clinical and biological effects of balneotherapy with selenium-rich spa water in patients with psoriasis vulgaris. Br J Dermatol. 133:1995;329.
8. Harvima R.J., Jägerroos H., Kajander E.O., et al. Screening of effects of selenomethionine-enriched yeast supplementation on various immunological and chemical parameters of skin and blood in psoriatic patients. Acta Derma Venereol (Stockh). 73:1993;88.
9. Schrauzer G.N. Nutritional selenium supplements products types, quality and safety . J Am Coll Nutr. 20:2001;1.
10. Ettehadi P., Greaves M.W., Wallach D., Aderka D., Camp R.D.R. Elevated tumor necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol. 96:1994;146.
11. Terajima S., Higaki M., Igarashi Y., Nogita T., Kawashima M. An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Arch Dermatol Res. 290:1998;246.
12. Brockhaus M., Schoenfeld H.-J., Schlaeger E.-J., Hunziker W., Lessauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA. 87:1990;3127.
13. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., Breathnach S.M. Localisation of tumor necrosis factor alpha (TNF-α) and its receptors in normal and psoriatic skin epidermal cell express the 55-kD but not the 75-kD TNF receptor . Clin Exp Immunol. 94:1993;354.
14. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 265:1990;1531.
15. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilisation of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323.
16. Gruschwitz M.S., Albrecht M., Vieth G., Haustein U.-F. In situ expression and serum level of tumor necrosis factor-α receptors in patients with early stages of systemic sclerosis. J Rheumatol. 24:1997;1936.
17. Aderka D., Engelmann H., Hornik V., et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51:1991;5602.
18. Simon M. Jr, Gruschwitz M.S. In situ expression and serum levels of tumor necrosis factor alpha receptors in patients with lichen planus. Acta Derm Venereol (Stockh). 77:1997;191.
19. Griffiths C.E.M., Boffa M.J., Gallatin W.M., Martin S. Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in psoriasis. Acta Derm Venereol (Sockh). 76:1996;2.
20. Kirby B., Boffa M.J., Nayak N., Gallatin W.M., Martin S., Griffiths C.E.M. The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumor necrosis factor-receptor 1 in psoriasis. Br J Dermatol. 145:2001;1027.
21. Fredriksson T., Petersson V. Severe psoriasis oral therapy with a new retinoid . Dermatologica. 157:1978;238.
22. Art U., Volcan M., Aras N.K. Determination of selenium in diet by Zeeman effect graphite furnace atomic absorption spectrometry for calculation of dietary intakes. J Agric Food Chem. 39:1991;2180.
23. Bonifati C., Trento E., Carducci M., et al. Soluble E-selectin and soluble tumor necrosis factor receptor (60 kD) serum levels in patients with psoriasis. Dermatology. 190:1995;128.
24. Fairris G.M., Perkins P.J., Lawson A.D., Blake G.B. The pharmacokinetics of selenium in psoriasis and atopic dermatitis. Acta Derm Venereol (Stockh). 68:1988;434.
25. Arenholt-Bindslev D., Abdulla M., Jepsen A., Pedersen E.J. Effect of organic and inorganic selenium on human keratinocytes. Trace Elem Med. 5:1988;29.